BTIG Raises its Price Target on SOPHiA GENETICS (SOPH) to $8

On April 15, 2026, BTIG raised its terms people connected SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The steadfast said absorption “signaled assurance crossed the business” pursuing capitalist meetings with President and incoming CEO Ross Muken, CFO George Cardoza, and Head of Strategy Kellen Sanger.

In March, SOPHiA GENETICS SA (NASDAQ:SOPH) reported Q4 EPS of (28c) compared to (23c) a twelvemonth earlier, portion gross roseate to $21.7 cardinal from $17.7 million. The institution said show was driven by 45% year-over-year maturation successful North America and 32% maturation successful the Asia Pacific. CEO Jurgi Camblong said the institution finished 2025 with beardown momentum, with Q4 gross up 22% and full-year gross expanding 19%.

Source: Unsplash

For 2026, SOPHiA GENETICS expects gross of $92 cardinal to $94 million, supra statement estimates of $76.47 million, representing maturation of astir 20% to 22% twelvemonth implicit year. The institution besides expects adjusted EBITDA successful the scope of ($29 million) to ($32 million).

SOPHiA GENETICS SA (NASDAQ:SOPH) provides cloud-based bundle tools that assistance healthcare providers analyse analyzable objective information and make insights crossed aggregate diagnostic platforms.

While we admit the imaginable of SOPH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.